Orthobiologics are the wrong treatment when the result you hope for is not the result the biology is likely to give. Most often that means you expect cartilage to be rebuilt, while the real effect is on symptoms and function. A 2026 survey in the Orthopaedic Journal of Sports Medicine asked 357 orthopedic patients at one United States academic medical center. 66.9% believed orthobiologics could treat cartilage injuries. That is exactly the mismatch that has to be cleared up before anyone books a procedure.
What does it mean when orthobiologics are not the right treatment?
It usually means the goal, the way the treatment works, and your own medical picture do not line up. That is not the same as saying “orthobiologics do not work.” And it is not the same as “orthobiologics are wrong for you permanently.”
We keep those three apart. Most decisions here put conservative care first. Then we adjust when conservative care has not reached the goal. A treatment that does not fit today can fit later, once the target is clearer.
Does PRP regrow cartilage, or does it control pain?
This is the most common mismatch we see. In the 2026 survey of those 357 patients, cartilage injury was the second most common condition patients thought orthobiologics could manage. Only pain and inflammation ranked higher, chosen by 70.9%.
In clinic, that shows up as frustration after an earlier PRP shot. Or it shows up as letdown that a follow-up scan looks the same. Our job is to link what you hope for with what is likely to happen in the tissue. Then we pick a next step you can really live with.
Setting the target before discussing any product
We start by defining what success means to you in plain terms. That might be pain during one activity, morning stiffness, swelling, or getting back a certain movement. Only then do we confirm which tissue problem we are trying to fix.
That is why a talk about a bone-on-bone knee does not start with a list of shots. It starts with the medical picture, and with an honest account of what biology and time will allow.
When the mechanism you want is not the mechanism that operates
Even when a biologic is given correctly, the repair process patients picture is often not the one doing the work. Sachs and colleagues wrote about cell-based orthobiologic therapies in Clinics in Sports Medicine in 2025. They state that these processes are likely not happening, and not leading to tissue regrowth, in most clinical settings where these agents are used today.
The same authors call the hope of true regrowth from so-called mesenchymal stem cells largely aspirational at this point. They describe the effect of these cell-based therapies as mostly symptom modifying. They say it is not disease modifying or structure modifying with true tissue regrowth.
Symptom modification is not structure change
If your plan is built around cartilage repair, the risk is that the result you want is not the result the treatment is most likely to give. That is a reason to change the plan. It is not a reason to quietly go ahead and hope.
We still consider orthobiologics where they fit, as a bridge or as one part of a broader plan. In advanced knee osteoarthritis, we frame PRP the way the trial authors framed it: a safe bridge therapy before joint replacement. We do not present a single shot as a structural fix when the reasoning is thinner than the hope.
What if your MRI and your pain do not point to the same problem?
You can have worn-down findings on a scan while something else drives the pain. It might be irritated soft tissue, how load is spread, or metabolic inflammation in the whole body. The reverse happens too: real symptoms with no single clear target on imaging.
When symptoms and the treatment target do not line up, shot decisions turn into trial and error. We try to close that gap with a terrain-first evaluation before anything is injected.
Terrain-first evaluation can change the direction entirely
Our terrain focus looks at the metabolic and whole-body factors that affect tissue healing and how joints behave. When we find causes that can be changed, orthobiologics may still belong in the plan. But they stop being the whole plan, and their timing usually changes.
When timing and cost make it the wrong moment
Even a fair candidate procedure can be the wrong choice this month. Sachs and colleagues report that orthobiologic use has grown fast. Yet there is little research on costs, and prices are not clear across the country. A survey of physicians who offer regenerative procedures showed patient costs varied widely. No study linked cost to results.
That makes it hard for a patient to compare options on value. If you cannot follow a shot with the rehab and follow-up it depends on, the shot is not the right next step yet.
How we handle this
We do not publish a single price for a procedure, because what a plan involves depends on the findings. What we do is go over the details with you directly during the evaluation. That way the decision rests on facts, not on guesswork.
When a knee replacement conversation should not be deflected
Many patients come wanting to avoid knee replacement, and we take that seriously. We also keep it honest. An alternative that is not working is not an alternative. It is a delay.
Bone marrow aspirate concentrate and Lipogems come up the same way. We weigh them against your tissue target, your past treatments, and your terrain, and we use them where that weighing points, not as automatic stand-ins for a decision that has already become necessary. Conservative care comes first. When it has truly run its course, surgery is a fair step. This practice provides it, since Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon.
When the pain generator is somewhere else
Orthobiologics into the disc may help some spine problems and not others. What decides it is where the pain really comes from, not which procedure is on hand. The same logic applies to peptide medicine. It is a medical and teaching topic here, matched to your evaluation. It does not replace finding the source of the problem.
What are the alternatives when orthobiologics do not fit?
We revise the plan instead of just saying no. Usually that means changing the target or the order. We may fix whole-body causes first. Or we may use a tool that fits the problem better than a shot would.
Regen.MD is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport. Directions are on our St. Louis clinic page. The full list of procedures we do perform is on our orthobiologics services page.
How the same decision is made when the trigger was an injury rather than gradual wear is set out in “Your body creates the healing.”
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
Frequently Asked Questions
How do I know whether orthobiologics are wrong for my knee pain?
The test is whether your pain pattern and tissue target match what the treatment can really do. If your goal is cartilage repair or structural change, that is where the evidence is weakest. There, we would advise against going ahead on those terms. How we run that check is described in our approach to clinical evaluation.
My MRI says “cartilage damage” — is PRP worth trying?
That decision is not made on MRI wording alone. In the 2026 survey of 357 orthopedic patients, two-thirds believed orthobiologics could treat cartilage injuries. The cited evidence does not support that hope. How we read imaging against symptoms is covered in the Regen.MD library.
What are intraosseous and subchondral PRP, and when are they the wrong choice?
Both place the shot in a specific area of bone next to the joint. That is based on a medical guess about where the pain comes from. So they are the wrong choice when the pain source is somewhere else, or when the goal is structural regrowth. The targets are described on our orthobiologics services page.
Can BMAC replace surgery for a bone-on-bone knee?
It should not be presented that way. The cited 2025 review calls cell-based therapies mostly symptom modifying, not structure modifying. In advanced knee osteoarthritis, PRP is framed as a bridge before joint replacement. When surgery is truly the right step, it is available here. The conditions we evaluate along that path are listed on our conditions page.
Should I consider peptide medicine instead of an injection?
Not as a swap. If the main driver looks whole-body and metabolic, not a local cartilage or tendon target, a different plan may fit better. Peptides are covered here as a medical and teaching topic, not as a stand-in procedure. The approach is on our peptide therapy page.
Who should not get PRP injections?
PRP fits when the pain comes from the spot being injected, when your scans and your symptoms point at the same target, and when you can follow the shot with the rehab and follow-up it depends on. It is the wrong fit when the goal is regrowing cartilage, or when those pieces are not yet in place. A poor fit today can become a good fit once the target is clear.
What causes PRP to fail?
Most often the plan, not the platelets. The hope was rebuilt cartilage when the real effect is on symptoms and function. Or the shot was aimed at a scan finding while the pain came from soft tissue, how load is spread, or metabolic inflammation. Skipping the rehab that should follow is another cause. A terrain-first evaluation before anything is injected is how we close those gaps.
Sources
- Garcia JR, Pallone LV, Gilat R, et al., “What Do Patients Know About Orthobiologics? Perceived Efficacy, Safety, and Factors Influencing Treatment Decisions,” Orthopaedic Journal of Sports Medicine, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12929896/ — cross-sectional survey of 357 eligible respondents at Rush University Medical Center, October 2023 to April 2024. Referenced for the finding that pain and inflammation were most frequently selected (n = 253; 70.9%), followed by cartilage injuries (n = 239; 66.9%).
- Sachs JP, Mufti YN, Bi AS, Cole BJ, “Economic Realities of Orthobiologics,” Clinics in Sports Medicine, 2025;44(4):827–840, https://doi.org/10.1016/j.csm.2024.10.011 — referenced for the statements that the regenerative mechanisms of cell-based orthobiologics are likely not actively occurring nor leading to tissue regeneration in most clinical settings, that true regeneration from mesenchymal stem cells is largely aspirational at this juncture, that their impact is predominantly symptom modifying rather than disease or structure modifying, and that there is sparse literature on the economic landscape with limited cost transparency and significant variability in patient costs.